Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPALA: Cabotegravir and Rilpivirine in HIV-1 Positive Adults
NCT05546242Phase 3Completed
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by MRC/UVRI and LSHTM Uganda Research Unit. Primary endpoint: HIV-1 viral load at 12 months. Started Dec 2022; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05546242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546242.